NEO-PV 01
- Generic Name
- NEO-PV 01
NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma
Phase 1
Recruiting
- Conditions
- Metastatic MelanomaMelanoma
- Interventions
- First Posted Date
- 2021-06-18
- Last Posted Date
- 2025-03-05
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 30
- Registration Number
- NCT04930783
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.
Phase 1
Recruiting
- Conditions
- Lymphocytic Leukemia
- Interventions
- First Posted Date
- 2017-07-17
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 15
- Registration Number
- NCT03219450
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
NeoVax Plus Ipilimumab in Renal Cell Carcinoma
- First Posted Date
- 2016-11-01
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Patrick Ott, MD, PhD
- Target Recruit Count
- 19
- Registration Number
- NCT02950766
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath